UOC
TGTX icon

UBS O'Connor’s TG Therapeutics TGTX Stock Holding History

UBS O'Connor’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40,000
Closed -$55K – 458
2024
Q4 		$55K Buy
40,000
+20,000
+100% +$574K ﹤0.01% 364
2024
Q3 		$6.5K Sell
20,000
-50,000
-71% -$1.09M ﹤0.01% 474
2024
Q2 		$57.8K Sell
70,000
-50,000
-42% -$798K ﹤0.01% 445
2024
Q1 		$18K Buy
120,000
+70,000
+140% +$1.12M ﹤0.01% 464
2023
Q4 		$55K Buy
+50,000
New +$581K ﹤0.01% 425

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS O'Connor's TGTX Position: Q3 2025 in Review

UBS O'Connor sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 19,000 shares — an estimated $684K sold.

UBS O'Connor first reported a position in TGTX in Q3 2024 and held it in 2 quarters. The position peaked at $899K in Q3 2024. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • UBS O'Connor reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 19,000 TG Therapeutics shares in Q3 2025, an estimated $684K.
  • UBS O'Connor first reported a position in TG Therapeutics in Q3 2024 and held it in 2 quarters.
  • UBS O'Connor's TG Therapeutics position peaked at $899K in Q3 2024.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.